#92: Syntara Phase 2 Success, Geopolitics and Uranium

About this episode

The episode discusses Syntara's Phase 2 results in myelofibrosis, market reactions, and future funding possibilities.

Syntara’s highly anticipated Phase 2 results in myelofibrosis—what the data tells us, why the market sold off, and what might come next in terms of funding or partnership.

Topics covered

• healthcare
• investing
• geopolitics
• pharmaceuticals
• uranium

Keywords

• Syntara
• Phase 2 results
• myelofibrosis
• market sell-off
• funding
• partnership

More episodes of Frazis Capital Podcast

• #100: Market Update & Launch of ROAR · June 12, 2026 · 32 min
• #99: ETF Launch - ASX:ROAR · June 2, 2026 · 37 min
• #98: AI Agents, Software Collapse & the Next Tech Cycle · February 2, 2026 · 39 min
• #97: AI Has Entered the Takeoff Phase · January 12, 2026 · 21 min
• #96: 99% of people missed it. You have 33 minutes to catch up. · January 5, 2026 · 33 min
• #94: Nvidia’s Red Flags, NeoCloud Bubble & the Quiet Quant Crash · December 28, 2025 · 39 min